SCHEMBL3336010

SCHEMBL3336010

CC(C)NC(=O)c1ccc(-c2ccc3nc(N)nc(OCCO)c3c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 1/20 0.44
IP6K3 Q96PC2 1/20 0.44
IP6K2 Q9UHH9 1/20 0.44
MAP4K4 O95819 2/20 0.44
MINK1 Q8N4C8 2/20 0.44
TNIK Q9UKE5 2/20 0.44
XDH P47989 2/20 0.41
HRH3 Q9Y5N1 3/20 0.41
POLB P06746 1/20 0.41
RIPK1 Q13546 1/20 0.40
BACE1 P56817 1/20 0.40
ROCK2 O75116 3/20 0.40
ROCK1 Q13464 2/20 0.39
DHFR P00374 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
LRRK2 Q5S007 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3337671 0.94 IP6K1 (0.43) IP6K1IP6K3IP6K2MAP4K4MINK1
SCHEMBL3340058 0.90 IP6K1 (0.45) IP6K1IP6K3IP6K2MAP4K4MINK1
SCHEMBL3336054 0.89 HPGD (0.42) POLB
SCHEMBL3341492 0.88 ALDH1A1 (0.39) MAP4K4POLBDHFRCYP3A4
SCHEMBL3336878 0.86 TRIM58 (0.46) IP6K1IP6K3IP6K2MAP4K4MINK1
SCHEMBL3336523 0.86 IP6K1 (0.47) IP6K1IP6K3IP6K2MAP4K4MINK1
SCHEMBL3337490 0.84 LMNA (0.44) MAP4K4BACE1ROCK2ROCK1
SCHEMBL3332984 0.83 MEN1 (0.46) RIPK1BACE1
SCHEMBL3334266 0.83 PIK3CA (0.42) MAP4K4CYP3A4
SCHEMBL3338723 0.83 HDAC4 (0.41) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 IP6K1 3654/4885IP6K3 2476/4885IP6K2 3315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.